Anticonvulsants / antiepileptic drugs are a type of drugs that are used to prevent or treat seizures or convulsions by controlling abnormal electrical activity in the central nervous system (CNS).

• Epilepsy: A disorder of brain function (collection of various syndromes) characterized by recurrent seizures that have a sudden onset.
• Seizure: Refers to an uncontrollable physiological response to a sudden discharge of excessive, abnormal electrical energy from nerve cells in the brain.
• Convulsion: A specific type of seizure characterized by tonic–clonic muscular reactions to excessive electrical energy.
• Generalized seizure: A seizure that begins in one area of the brain and rapidly spreads throughout both hemispheres. Almost always causes loss of consciousness.
• Partial seizures: Also called focal seizures; seizures involving one area of the brain typically one hemisphere that do not spread throughout the entire body. May occur with or without impairment of awareness.
• Absence seizure: Type of generalized seizure that is characterized by sudden, temporary loss of consciousness, sometimes with staring or blinking for 3 to 5 seconds; formerly known as a petit mal seizure.
• Tonic–clonic seizure: Type of generalized seizure that is characterized by serious clonic–tonic muscular reactions and loss of consciousness, with exhaustion and little memory of the event on awakening; formerly known as a grand mal seizure.
• Status epilepticus: State in which seizures rapidly recur; the most severe form of generalized seizure.
• Antiepileptic: Drug used to treat the abnormal and excessive energy bursts in the brain that are characteristic of epilepsy.

Seizures can be viewed as the result of an imbalance between inhibitory and excitatory processes in the brain that produces either too little inhibition or too much excitation.

• Excitatory: Excitatory neurotransmitters “excite” the neuron and cause it to “fire off the message,” meaning, the message continues to be passed along to the next cell.
  • Examples: Glutamate, Epinephrine, and Norepinephrine.
• Inhibitory: Inhibitory neurotransmitters block or prevent the chemical message from being passed along any farther.
  • Examples: Gamma-aminobutyric acid (GABA), Glycine, and Serotonin.
• Modulatory: Influence the effects of other chemical messengers. They “tweak” or adjust how cells communicate at the synapse and affect a larger number of neurons at the same time.

1. Increase the inhibitory neurotransmitter GABA (Gamma-Amino-butyric Acid).
2. Decrease the excitatory neurotransmitter system (Glutamate).
3. Block voltage-gated inward positive currents of Na+ or Ca2+.
4. Increase outward positive current K+.

These drugs affect the entire brain and reduce the chance of sudden electrical outbursts. They stabilize nerve membranes by blocking channels or altering receptor sites. Because they work generally on the CNS, sedation often results.

• 1. Hydantoins: Phenytoin, Ethotoin, Fosphenytoin, Mephenytoin, Phenacemide.
• 2. Barbiturates and Barbiturate-Like Drugs: Phenobarbital (Phenobarbitone), Amobarbital, Mephobarbital, Primidone.
• 3. Benzodiazepines: Clonazepam, Diazepam, Midazolam, Chlordiazepoxide, Alprazolam, Bromazepam.
• 4. Succinimides: Ethosuximide, Methsuximide, Phensuximide.
• 5. Oxazolidinediones: Trimethadione, Paramethadione.
• 6. Valproates / Valproic Acid Derivatives: Valproic acid, Sodium Valproate, Divalproex sodium.
• 7. Sulfonamides: Acetazolamide, Zonisamide.

These drugs stabilize nerve membranes either directly (altering Na+ and Ca2+ channels) or indirectly (increasing GABA activity). Carbamazepine and oxcarbazepine are often used as monotherapy, while others are used as adjunctive therapy.

• 1. Carboxamides: Carbamazepine, Oxcarbazepine.
• 2. GABA Analogs: Gabapentin, Pregabalin.
• 3. Triazines: Lamotrigine.
• 4. Fructose derivatives: Topiramate.

• Carbamazepine (also listed above for partial), Magnesium Sulphate (especially for eclampsia).

Because hydantoins are generally less sedating than many other antiepileptics, they may be the drugs of choice for patients unwilling to tolerate heavy sedation. However, due to significant adverse effects and a narrow therapeutic index, benzodiazepines have replaced them in many acute situations, and newer anticonvulsants are often preferred for long-term maintenance. Phenytoin is unique for its non-linear (Michaelis-Menten) kinetics, meaning small dose increases can lead to disproportionately large increases in serum levels and toxicity.

• Mechanism of Action:
  • Primary action: Inhibits voltage-gated Na+ channels in the "inactive" state, which prevents the influx of sodium into the neuron.
  • This action limits the sustained high-frequency repetitive firing of action potentials, thereby stabilizing nerve membranes and preventing the spread of seizure activity.
  • At high concentrations, it may also influence calcium channels and neurotransmitter release (GABA and Glutamate).
• Pharmacokinetics:
  • Absorbed slowly and somewhat variably from the small intestine; absorption is highly dependent on the formulation (capsule vs. suspension).
  • Distributed widely and is highly protein-bound (approx. 90% to albumin), meaning patients with low protein levels (malnutrition, renal failure) are at higher risk of toxicity despite "normal" total drug levels.
  • Metabolized by the liver (CYP2C9/2C19) to inactive metabolites; it saturates its own metabolic enzymes at therapeutic doses.
  • Excreted in the urine as metabolites.
• Indications:
  • Generalized tonic–clonic (Grand Mal) seizures and complex partial seizures.
  • Short-term control of status epilepticus (usually administered as a loading dose following a benzodiazepine).
  • Trigeminal neuralgia (as a second-line agent behind carbamazepine).
  • Cardiac arrhythmias, specifically those induced by digitalis toxicity (Class 1b antiarrhythmic).
  • Prevention of early post-traumatic seizures after neurosurgery or severe head trauma.
• Dose (Phenytoin):
  • Adult (Oral): 100 mg TDS (150-300mg daily) as a single or 2 divided doses. Up to 300–400 mg/day; doses must be adjusted based on serum trough levels (target: 10–20 mcg/mL).
  • Children (Oral): Initially 5 mg/kg daily in 2 divided doses, adjusted to a maximum of 300mg daily.
  • Status Epilepticus/Arrhythmias: Loading dose 250mg QID for 1 day, then 250mg TDS for two days. Maintenance: 300-400mg/day. Or 10–15 mg/kg IV (must not exceed 50mg/min in adults to avoid cardiovascular collapse).
• Contraindications:
  • Hypersensitivity to hydantoins.
  • Cardiovascular: Sinus bradycardia, sino-atrial block, 2nd and 3rd-degree heart block (due to effects on myocardial conduction).
  • Systemic: Stroke, active hepatitis, or severe hepatic impairment.
  • Pregnancy: Known teratogen (Fetal Hydantoin Syndrome), though used if seizure risks to the mother outweigh fetal risks (Category D).
• Adverse Effects:
  • Gum hyperplasia (Gingival hyperplasia): Overgrowth of gum tissue, occurring in about 20-50% of long-term users.
  • CNS Toxicity: Nystagmus (earliest sign of toxicity), ataxia (staggering gait), slurred speech, confusion, and drowsiness.
  • Sensory/Motor: Lethargy, fatigue, diplopia (double vision).
  • Gastrointestinal: Constipation, nausea/vomiting.
  • Dermatological/Systemic: Hirsutism (excessive hair growth), skin rash (risk of Stevens-Johnson Syndrome), and interference with vitamin D metabolism (osteomalacia).
  • Hematological: Megaloblastic anemia (due to interference with folate metabolism).
• Drug Interactions:
  • Potent enzyme inducer: Decreases effects of oral contraceptives, corticosteroids, warfarin, and furosemide.
  • CNS interactions: Alcohol and other CNS depressants increase respiratory depression and sedation.
  • Metabolic inhibitors: Phenytoin's effect is decreased by barbiturates, carbamazepine, and folic acid; conversely, its levels are increased by valproate and cimetidine.
• Nursing Considerations:
  • Administration: Should be taken with food to decrease GI upset; when giving IV, only flush with Normal Saline (dextrose causes precipitation).
  • Patient Education: Advise maintaining excellent oral hygiene and regular dental checkups to manage gum hyperplasia.
  • Safety: Do not withdraw abruptly as this may precipitate status epilepticus. Monitor for "purple glove syndrome" at the IV site.

Barbiturates are among the oldest classes of anticonvulsants. They act as non-selective CNS depressants that inhibit impulse conduction in the ascending reticular activating system (RAS), depress the cerebral cortex, alter cerebellar function, and depress motor nerve output. While effective, their use is often limited by their significant sedative properties and potential for dependence.

• Mechanism of Action:
  • Bind to the GABA-A receptor at a specific barbiturate binding site.
  • Mechanism: Prolong the duration of GABA-mediated chloride channel openings (unlike benzodiazepines which increase frequency).
  • This increases chloride influx, hyperpolarizing the neuron and stabilizing nerve membranes against excitability.
• Pharmacokinetics:
  • Well absorbed orally with high bioavailability.
  • Widely distributed throughout body tissues and crosses the blood-brain barrier easily.
  • Metabolized extensively by the liver (induces its own metabolism over time).
  • Excreted in the urine; alkalinization of urine can speed up excretion in toxicity cases.
• Indications:
  • Generalized tonic–clonic seizures and partial seizures.
  • First-line agent for neonatal seizures.
  • Febrile convulsions in children (prophylaxis and acute treatment).
  • Emergency control of status epilepticus and acute seizures in eclampsia/tetanus.
  • Non-epileptic uses: Short-term treatment of anxiety (anxiolytic) or insomnia (hypnotic).
• Dose (Phenobarbitone):
  • Adult: 60–100 mg/day Orally at night to capitalize on sedative effects. 200–320 mg IM or IV for acute episodes.
  • Children: 3–8 mg/kg per day Orally (maintenance). For status epilepticus: 15–20 mg/kg IV infused slowly over 10–15 min.
  • Febrile convulsion: 8mg/kg daily.
• Contraindications:
  • Hypersensitivity to barbiturates.
  • Absence seizures: Can actually worsen absence (petit mal) seizures.
  • Porphyria: Absolute contraindication as it induces enzymes that increase porphyrin production.
  • Respiratory: Severe respiratory depression or severe COPD.
  • Organ Failure: Severe liver impairment (risk of hepatic coma).
• Adverse Effects:
  • CNS: Heavy sedation and somnolence; ataxia and nystagmus (signs of intoxication).
  • Respiratory: Potent respiratory depression, especially when given IV.
  • Pediatric/Geriatric: Paradoxical excitement or behavioral disturbances (hyperactivity in children; confusion in the elderly).
  • Mood: Mental depression and cognitive impairment with long-term use.
  • Dermatological: Allergic skin reactions (can range from simple rash to exfoliative dermatitis).
  • Hematological: Megaloblastic anemia and Vitamin K deficiency in newborns of treated mothers.
• Drug Interactions:
  • Enzyme Induction: Increases the metabolism (reducing the effect) of carbamazepine, digoxin, oral contraceptives, and anticoagulants (Warfarin).
  • Toxicity: Sodium valproate inhibits the metabolism of phenobarbitone, leading to a dangerous rise in barbiturate levels and toxicity.
  • Additive Depression: Alcohol and antihistamines significantly potentiate CNS and respiratory depression.

• Mechanism of Action: Potentiate the effects of GABA by increasing the frequency of GABA-mediated chloride channel openings. Causes muscle relaxation and relieves anxiety.
• Indications: Drug of choice for Status epilepticus (IV). Severe convulsions, febrile convulsions, anxiety disorders, insomnia, control of muscle spasms, alcohol withdrawal, convulsions due to poisoning.
• Dose:
  • Status Epilepticus: 5mg/minute IV (10mg IV slowly, repeat if necessary).
  • Adult (Oral for anxiety): 2–10 mg BD to QID.
  • Children: 200-300mcg/kg.
  • Rectal: Adult/Child >3yrs: 10mg. Child 1-3yrs: 5mg.
• Contraindications: Sleep apnea, severe respiratory depression, acute angle glaucoma, acute alcohol intoxication, comatose patients, infants < 1 month.
• Adverse Effects: Drowsiness, sedation, dependence, hypotension, muscle weakness, ataxia, confusion, skin rash, amnesia, urinary retention.
• Key Issues: Administer with food/water but not grapefruit juice. Heavy smoking accelerates metabolism. Decreases dose slowly over 8-12 weeks to prevent withdrawal status epilepticus.

• Indications: Myoclonic seizures, absence seizures, panic disorders, acute manic episodes.
• Dose: Oral 1mg at night, titrate up to 4-8mg daily.
• Adverse Effects: Drowsiness, fatigue, changes in libido/appetite, ataxia, palpitations, dry mouth.
• Interactions: Concomitant use with sodium valproate may induce absence seizures.

• Pharmacokinetics: Rapidly and completely absorbed, metabolized extensively in the liver to inactive metabolites.
• Indications: Drug of choice for Absence seizures (petit mal). Also used for myoclonic seizures.
• Dose: Adult/Child >6yrs: Initial 250mg BD. Usual 500mg BD.
• Adverse Effects: Anorexia, nausea/vomiting, epigastric pain, weight loss, photophobia, hiccups, dizziness, mild euphoria, agranulocytosis.
• Nursing Considerations: Administer with food or milk to prevent severe GI upset. Abrupt withdrawal precipitates petit mal seizures.

• Mechanism of Action: Enhances GABA transmission, blocks Na+ channels, and activates K+ channels.
• Indications: Generalized tonic-clonic seizures, partial seizures, atonic seizures, myoclonic seizures, acute manic phase of bipolar disorder, migraine prophylaxis.
• Dose: Initial 600mg daily in divided doses. Maintenance: 1-2g daily.
• Contraindications: Family history of severe hepatic dysfunction, porphyria, pancreatitis, pregnancy (highly teratogenic).
• Adverse Effects: Nausea/vomiting, increased appetite/weight gain, sedation, ataxia, transient hair loss, thrombocytopenia, menstrual disturbances.
• Drug Interactions: Increases plasma concentration of phenobarbital, primidone, phenytoin. Aspirin/cimetidine increases valproate effects.

• Mechanism of Action: Interferes with GABA uptake.
• Indications: Adjunct in treating partial seizures. Widely used for Neuropathic pain, postherpetic neuralgia, and trigeminal neuralgia.
• Dose (Gabapentin): Adult 300mg on 1st day, 300mg BD 2nd day, then 300mg TDS (900-1800 mg/d).
• Adverse Effects: Peripheral edema, dry mouth, diarrhea, dyspepsia, tremor, ataxia, pharyngitis, amnesia, weight gain.
• Drug Interactions: Antacids containing aluminum/magnesium drastically reduce gabapentin absorption.

• Mechanism of Action: Inhibits voltage-gated Na+ channels.
• Pharmacokinetics: Absorbed slowly, crosses placenta, metabolized in liver.
• Indications: Drug of choice for partial seizures and generalized tonic-clonic seizures. Mixed seizure disorders, Trigeminal neuralgia, bipolar disorder prophylaxis, neuropathic pain.
• Dose: Initial 100-200mg 1-2 times daily. Maintenance 400-1200mg daily in divided doses.
• Adverse Effects: Blurred vision, drowsiness, ataxia, confusion, agitation, GI upset, thrombocytopenia, agranulocytosis.
• Drug Interactions: Clarithromycin, erythromycin, cimetidine inhibit its metabolism (leading to toxicity). It induces enzymes that decrease the effectiveness of oral contraceptives. Avoid grapefruit juice!

• Assess for contraindications: Known allergies, history of bone marrow suppression, renal stones, or hepatic dysfunction that might interfere with drug metabolism.
• Pregnancy/Lactation Status: Many AEDs (Carbamazepine, valproate, gabapentin) are dangerous to a fetus. Counsel women of childbearing age on barrier contraceptives.
• Physical Exam: Inspect skin for color/lesions (rashes). Assess pulse and BP. Assess level of orientation, affect, reflexes, and bilateral grip strength.
• Laboratory Monitoring: Monitor renal/liver function tests (LFTs). Monitor CBC with differential closely to identify changes in bone marrow function (agranulocytosis/thrombocytopenia).

• Seizure Control: Monitor patient response to the drug (decrease in incidence or complete absence of seizures).
• Adverse Effects: Continually evaluate for CNS changes, GI depression, bone marrow suppression, severe dermatological reactions, or liver toxicity.
• Patient Compliance: Ensure the patient understands the long-term nature of therapy, restrictions, and the absolute necessity of not stopping the drug abruptly.